Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Novo Nordisk Just Bought the Next Big Thing in Weight Loss

Daniel Kim Views  

Novo Nordisk secures international rights to Triple-G weight loss treatment through an exclusive licensing deal with United Laboratories International. / DB
Medical Today

Big news in the world of weight loss treatments! Novo Nordisk has just locked down global rights to a promising new therapy, Triple-G, thanks to an exclusive licensing deal with United Laboratories International.

This new deal is a huge win for Novo Nordisk, the Danish pharmaceutical giant, which has been making strategic moves in the $150 billion obesity treatment market. The agreement gives Novo the rights to develop, manufacture, and commercialize UBT251, a cutting-edge weight loss treatment.

So, what makes UBT251 so special? While most weight loss treatments, like Wegovy, target the GLP-1 hormone, UBT251 takes things up a notch by targeting three hormones: GLP-1, GIP, and Glucagon.

Hence, the name Triple-G. This unique approach aims to deliver superior weight loss results, giving it a competitive edge in the ever-growing obesity treatment market. Novo has been under pressure recently after its next-gen obesity treatment, CagriSema, didn’t meet expectations.

Meanwhile, in mid-stage clinical trials, Eli Lilly’s rival, Retatrutid, has shown impressive results, up to 24.2% weight loss. However, early data on UBT251 look promising, suggesting it could compete with Retatrutide, making this licensing deal a crucial move for Novo.

The agreement includes an upfront payment of $200 million and the potential for up to $1.8 billion in milestone payments. It’s a big bet, but if UBT251 lives up to its promise, it could be a game-changer in weight loss treatment.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • New Blood Test Could Spot Alzheimer’s Early—With 92% Accuracy
  • Study Finds Link Between Irregular Heartbeat and Early Dementia
  • This Common Vaccine May Help Protect Against Memory Loss
  • Lilly’s Weight-Loss Pill Looks Strong in Trials—Ozempic’s Reign in Jeopardy?
  • Why Do My Eyes Look Bruised for No Reason? Here’s What Could Be Going On
  • This Common Travel Outfit Could Melt Onto Your Skin in a Fire

Share it on...